Yasinska, Inna M

Abooali, Maryam; Yasinska, Inna M; Schlichtner, Stephanie; Ruggiero, Sabrina; Berger, Steffen M; Cholewa, Dietmar; Milošević, Milan; Bartenstein, Andreas; Fasler-Kan, Elizaveta; Sumbayev, Vadim V (2024). Activation of immune evasion machinery is a part of the process of malignant transformation of human cells. Translational oncology, 39(101805), p. 101805. Elsevier 10.1016/j.tranon.2023.101805

Schlichtner, Stephanie; Yasinska, Inna M; Lall, Gurprit S; Berger, Steffen M; Ruggiero, Sabrina; Cholewa, Dietmar; Aliu, Nijas; Gibbs, Bernhard F; Fasler-Kan, Elizaveta; Sumbayev, Vadim V (2023). T lymphocytes induce human cancer cells derived from solid malignant tumors to secrete galectin-9 which facilitates immunosuppression in cooperation with other immune checkpoint proteins. Journal for immunotherapy of cancer, 11(1) BioMed Central 10.1136/jitc-2022-005714

Schlichtner, Stephanie; Yasinska, Inna M; Klenova, Elena; Abooali, Maryam; Lall, Gurprit S; Berger, Steffen M; Ruggiero, Sabrina; Cholewa, Dietmar; Milošević, Milan; Gibbs, Bernhard F; Fasler-Kan, Elizaveta; Sumbayev, Vadim V (2023). L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes. Oncoimmunology, 12(1), p. 2244330. Taylor & Francis 10.1080/2162402X.2023.2244330

Schlichtner, Stephanie; Yasinska, Inna M; Ruggiero, Sabrina; Berger, Steffen M; Aliu, Nijas; Prunk, Mateja; Kos, Janko; Meyer, N Helge; Gibbs, Bernhard F; Fasler-Kan, Elizaveta; Sumbayev, Vadim V (2022). Expression of the Immune Checkpoint Protein VISTA Is Differentially Regulated by the TGF-β1 - Smad3 Signaling Pathway in Rapidly Proliferating Human Cells and T Lymphocytes. Frontiers in medicine, 9, p. 790995. Frontiers 10.3389/fmed.2022.790995

Gibbs, Bernhard F; Gonçalves Silva, Isabel; Prokhorov, Alexandr; Abooali, Maryam; Yasinska, Inna M; Casely-Hayford, Maxwell A; Berger, Steffen Michael; Fasler-Kan, Elizaveta; Sumbayev, Vadim V (2015). Caffeine affects the biological responses of human hematopoietic cells of myeloid lineage via downregulation of the mTOR pathway and xanthine oxidase activity. OncoTarget, 6(30), pp. 28678-28692. Impact Journals LLC 10.18632/oncotarget.5212